General Information of Drug (ID: DM6JLNT)

Drug Name
177-Lu-NeoB Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM6JLNT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ASP-7147 DMGDF2X Irritable bowel syndrome DD91.0 Phase 2 [3]
RC-3095 DMIG98L Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
177Lu-labelled NeoBOMB1 DM2TSMD Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
177Lu-AMBA DMFG1YA Breast cancer 2C60-2C65 Phase 1 [5]
BIM-26226 DM9F4LP Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [6]
kuwanon H DMVQDNR Discovery agent N.A. Investigative [7]
bombesin DMDFQ0Y Discovery agent N.A. Investigative [8]
PD 168368 DMFNQEA Discovery agent N.A. Investigative [9]
MK-5046 DMS7C6R Discovery agent N.A. Investigative [10]
bantag-1 DM4OT8M Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastrin-releasing peptide receptor (GRPR) TTC1MVT GRPR_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT03872778) [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay). U.S. National Institutes of Health.
2 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
3 Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
4 Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8.
5 Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48.
6 Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86.
7 Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
8 Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
9 Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11.
10 Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.